Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

Journal of virology - 1 Jan 2012

Putcharoen Opass, Lee Sun Hee, Henrich Timothy J, Hu Zixin, Vanichanan Jakapat, Coakley Eoin, Greaves Wayne, Gulick Roy M, Kuritzkes Daniel R, Tsibris Athe M N

Abstract excerpt

HIV CCR5 antagonists select for env gene mutations that enable virus entry via drug-bound coreceptor. To investigate the mechanisms responsible for viral adaptation to drug-bound coreceptor-mediated entry, we studied viral isolates from three participants who developed CCR5 antagonist resistance during treatment with vicriviroc (VCV), an investigational small-molecule CCR5 antagonist. VCV-sensitive and -resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CCR5 Receptor Antagonists

Share to HIV Envelope Protein gp120

Share to Piperazines

Share to Pyrimidines

Share to Quaternary Ammonium Compounds

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 22090117
DOI: 10.1128/JVI.06421-11
PMCID: PMC3255837

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.PMID 22090117Read ↗

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitorsSemantic proximity Read ↗

A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacitySemantic proximity Read ↗

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Semantic proximity Read ↗

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.Semantic proximity Read ↗

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected SubjectSemantic proximity Read ↗

HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for EntrySemantic proximity Read ↗

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.Semantic proximity Read ↗

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.Semantic proximity Read ↗

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and VicrivirocSemantic proximity Read ↗

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 CoreceptorSemantic proximity Read ↗

Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.Semantic proximity Read ↗

Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist VicrivirocSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.